Viewpoint Molecular Targeting, Inc. (“Viewpoint” ), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents,  announced that it has entered into a Memorandum of Understanding (MoU) with The National Nuclear Laboratory (NNL) to explore avenues to supply Pb-212 to researchers, and possibly clinicians, in the United Kingdom and Europe, using Viewpoint’s proprietary isotope generator, VMT-GEN.

VMT-GEN is an  isotope generator that provides therapeutic doses of Pb-212 for the Company’s therapeutics – part of its (“Theranostic”) programs for the treatment of cancers (including metastatic melanoma, neuroendocrine tumors, and other oncology indications in the company pipeline).

To read more please visit:

Viewpoint Molecular Targeting® Enters Agreement with UK-Based National Nuclear Laboratory, Ltd. to Advance Development of Targeted Alpha Therapy for Cancer

Source: VIEWPOINT